This isn't a good day for investors in Grail (NASDAQ: GRAL). The stock declined more than 50% by 1:30 p.m. today. The move comes on the day of its fourth-quarter earnings results, but more importantly, the release of its top-line results from a major trial of its Galleri multi-cancer early detection (MCED) test in England's National Health Service (NHS). As you have already surmised, the trial did not go as planned. What went wrong The first bullet point of the results release is what investors are focusi ...

Core Insights - CRISPR Therapeutics has achieved significant milestones, including the approval of Casgevy, the first gene-editing therapy using the CRISPR system for rare blood diseases [1] - Despite past achievements, the company has underperformed in the market, but upcoming catalysts in its pipeline have generated investor interest [2] - The company's gene-editing approach has the potential to transform treatment standards in areas with high unmet medical needs, with several promising medicines expected to show progress in the next 12 to 18 months [3] Pipeline Developments - Zugo-cel is a potential treatment for various cancers and autoimmune diseases, designed to overcome limitations of traditional CAR-T therapies by using healthy donor cells instead of patients' own cells [4][5] - Zugo-cel has received the Regenerative Medicine Advanced Therapy designation from the FDA, which aims to expedite the development of treatments with promising early clinical evidence [6] - Other pipeline candidates include CTX310, aimed at lowering bad cholesterol, and SRSD107, a next-generation anticoagulant [6]

Key Takeaways Prothena reported a Q4 loss of 45 cents per share, while revenues fell sharply year over year.Prothena expects 2026 net cash burn of $50M-$55M and projects up to $105M in milestone payments.Prothena's partnered pipeline includes late-stage studies with Roche and Novo Nordisk through 2029.Prothena Corporation (PRTA) reported fourth-quarter 2025 adjusted loss per share (excluding restructuring costs) of 45 cents, in line with the Zacks Consensus Estimate.In the year-ago quarter, the company had ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underper ...

Key Takeaways Insmed posted a wider Q4 loss of $1.54 per share as revenues jumped 153% to $263.8M.Brinsupri delivered $144.6M in Q4 sales; 2026 guidance calls for at least $1B.Arikayce sales rose 14% to $119.2M; R&D and SG&A expenses climbed sharply.Insmed (INSM) reported a fourth-quarter 2025 loss of $1.54 per share, wider than the Zacks Consensus Estimate of a loss of $1.07. In the year-ago quarter, the company had incurred a loss of $1.32.Quarterly revenues rose 153% year over year to over $263.8 million ...

NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 22.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Core Viewpoint - Grail Inc's stock is experiencing a significant decline due to the failure of its three-year cancer screening trial to meet its primary goal, despite reporting better-than-expected fourth-quarter results [1]. Group 1: Stock Performance - Grail Inc's stock is down 47.7%, trading at $53.11, marking its largest single-day percentage drop on record and the lowest level since September [1]. - Year-over-year, shares are still up 11%, but they are significantly lower than the record high of $118.84 reached on January 22 [2]. - Short interest constitutes 14.5% of the stock's available float, indicating a bearish sentiment among traders [2]. Group 2: Trading Activity - The stock has seen 41 times its average daily options volume, with notable activity in the February 60 call option, which expires today [3]. - New positions are being opened in the options market, suggesting increased trading interest despite the stock's decline [3].

Faruqi, LLP also encourages anyone with information regarding uniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the uniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). ...

Core Viewpoint - Analysts forecast that United Therapeutics (UTHR) will report quarterly earnings of $6.78 per share, reflecting a year-over-year increase of 9.5%, with anticipated revenues of $805.31 million, marking a 9.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Adcirca' will reach $4.62 million, a decrease of 1.6% from the year-ago quarter [5]. - The average prediction for 'Revenues- Orenitram' is $121.24 million, indicating a year-over-year increase of 12.5% [5]. - The consensus for 'Revenues- Other products' stands at $5.10 million, reflecting a year-over-year decline of 7.3% [5]. - 'Revenues- Remodulin' is expected to be $131.46 million, showing a decrease of 2.3% year over year [6]. - 'Revenues- Tyvaso' is projected to reach $488.25 million, indicating a year-over-year increase of 17.4% [6]. - 'Revenues- Unituxin' is expected to be $51.29 million, suggesting a significant decline of 24% year over year [6]. - 'Revenues- Nebulized Tyvaso' is forecasted at $144.35 million, reflecting a slight increase of 1.2% from the prior year [7]. - 'Revenues- Tyvaso DPI' is expected to reach $313.30 million, indicating a year-over-year increase of 14.7% [7]. - 'Revenues- United States' is projected to be $753.92 million, reflecting a change of 6.8% from the prior-year quarter [7]. - 'Revenues- Rest-of-World' is estimated at $28.71 million, suggesting a year-over-year decline of 4.9% [8]. Stock Performance - Over the past month, shares of United Therapeutics have returned +1.8%, contrasting with the Zacks S&P 500 composite's -0.8% change [8]. - Currently, UTHR holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

Core Viewpoint - Vertex Pharmaceuticals' stock has increased following its fourth-quarter results, but long-term investment potential lies with its partner CRISPR Therapeutics, which developed the gene-editing therapy Casgevy [1][2]. Group 1: Vertex Pharmaceuticals - Vertex reported higher sales projections for Casgevy, a gene-editing therapy for sickle cell disease and beta thalassemia, contributing to its profitability and revenue from cystic fibrosis treatments [2]. - The company's share price experienced a short-term spike but moderated afterward, losing most of its gains [2]. Group 2: CRISPR Therapeutics - CRISPR Therapeutics, based in Switzerland, is the developer of Casgevy, the first CRISPR-based gene therapy approved by the FDA, and stands to benefit from increased sales of this therapy [3]. - The company has a strong position in the market, as evidenced by its significant holding in Cathie Wood's Ark Innovation ETF, indicating investor confidence in its potential [4]. - CRISPR has five additional gene therapy candidates in clinical trials, which target larger patient populations than Casgevy, enhancing its long-term growth prospects [4]. - Notable candidates include CTX310, which has shown to reduce triglycerides and LDL cholesterol by over 80%, and CTX320 for atherosclerotic cardiovascular disease [5]. - The company is also developing SRSD107, a long-acting gene therapy for thrombosis, and CTX211, which aims to restore insulin production in type 1 diabetes patients [6]. - Despite not being profitable and experiencing a 64% decline in share price over the past five years, CRISPR has over $1.9 billion in cash, positioning it well for future development if Casgevy sales increase as anticipated [7].